We recently traveled to Pittsburgh, Pennsylvania for a State of the Science Summit™ on Ovarian Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center highlighted the many advances made with PARP inhibitors, the importance of molecular testing, considerations for the frontline treatment of newly diagnosed disease, as well as the best options for neoadjuvant therapy. Faculty also shed light on exciting immunotherapy combinations under exploration and shared key updates in the treatment of recurrent disease.